Kolexia
Saldana-Gerard Carolina Oncologie médicale
Saldana-Gerard Carolina
Oncologie médicale
Hôpital Henri Mondor
Créteil, France
100 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs de la prostate Tumeurs du rein Tumeurs prostatiques résistantes à la castration Leucopénie Léiomyomatose COVID-19 Neutropénie

Collaborateurs

Voir plus
Tournigand Christophe
Tournigand Christophe
Hôpital Henri Mondor, Créteil, France
Joly Charlotte
Joly Charlotte
Hôpital Henri Mondor, Créteil, France
Assaf Elias
Assaf Elias
Hôpital Henri Mondor, Créteil, France
Baumgaertner Isabelle
Baumgaertner Isabelle
Cabinet libéral, La Seyne-sur-Mer, France

Industries

Voir plus
A+A
16 collaboration(s)
Dernière en 2023
Ipsen
13 collaboration(s)
Dernière en 2023
Pfizer
9 collaboration(s)
Dernière en 2023
Sanofi
7 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
Data registration for multi-method qualification of additive manufactured components.
Additive manufacturing   02 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Essai Clinique (Unicancer)   29 août 2023
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm.
Journal of the European Academy of Dermatology and Venereology : JEADV   22 août 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
European journal of cancer (Oxford, England : 1990)   18 août 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
European urology   02 juin 2023
Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study.
Advances in radiation oncology   24 avril 2023
SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study
Essai Clinique (CHU Bordeaux)   10 mars 2023
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
International journal of molecular sciences   07 février 2023